Treatment News : Three Big HIV Days in May at the FDA - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 19, 2012

Three Big HIV Days in May at the FDA

by Tim Horn

The U.S. Food and Drug Administration (FDA) has three important advisory committees planned in May to review new strategies in prevention, treatment and diagnostic testing, according to an AIDS.gov blog post by Richard Klein, who heads the agency’s Office of Special Health Issues.

On May 10, the FDA’s Antiviral Drugs Advisory Committee (ADAC) will meet to discuss Gilead Sciences’ application seeking approval of Truvada (tenofovir plus emtricitabine) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquiring HIV.

The next day, on May 11, ADAC will reconvene to review Gilead’s application requesting marketing clearance for its “Quad” fixed-dose combination (FDC) tablet containing tenofovir and emtricitabine plus two still-unapproved agents: the integrase inhibitor elvitegravir and the novel boosting agent cobicistat. The advisory committee will vote on the quality of the FDC’s safety and efficacy data in clinical trials involving people living with HIV starting therapy for the first time or without known HIV genetic mutations associated with resistance to any of the four drugs in the tablet.

Finally, on May 15, the FDA’s Blood Products Advisory Committee will meet to evaluate data supporting the approval of OraQuick’s In-Home HIV antibody test. This is the first time a complete home-use rapid HIV test has been submitted to the agency for approval.

All advisory committee meetings are open to the public. They begin at 8 A.M. and are set to conclude around 5 P.M. on all three days.

The May 10 PrEP advisory committee meeting will be held in Room 1503 of the FDA’s White Oak Campus (10903 New Hampshire Avenue, Building 31 Conference Center) in Silver Spring, Maryland.

The May 11 Quad advisory committee meeting will be held at the Hilton DoubleTree Hotel (8727 Colesville Road) in Silver Spring.

The May 15 advisory committee meeting on home HIV testing will take place at the Hilton Washington DC/North (620 Perry Parkway) in Gaithersburg, Maryland.

The public is also invited to provide oral and/or written testimony on these topics, though the deadline for requesting time to speak at the May 10 meeting has passed and the deadline for submitting a request to speak at the May 11 meeting is today (April 19). Individuals interested in making formal oral presentations at the May 15 meeting have until April 30 to notify the FDA.

All pertinent information regarding the meetings, including instructions for submitting oral and written testimony, can be found using the links above.

While the FDA is not required to follow its advisory committees’ recommendations, it usually does so. Final approval decisions from the agency are expected to follow in the weeks following the advisory committee meetings.

Search: fda, antiviral drugs advisory committee, adac, blood products advisory committee, prep, truvada, quad, cobicistat, elvitegravir, oraquick, home, test, antibody, aids.gov


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 3 (of 3 total)    

Tested poz @ home, , 2012-04-25 01:34:46
Can anyone else here imagine the absolute horror that would come from testing poz for the first time in front of a trick that was using it as a screening agent? Home Access is brutal enough, with their half-baked "counseling". The idea of "your test was positive" being followed by "get out of my bed you filthy monster" is unthinkable. Bad idea. The probable implications for traumatized newly DXd people are unspeakable. Not that it's ever stopped te FDA before.

sheilame, , 2012-04-24 18:47:37
I will be excited only when FDA announces a cure for HIV/AIDS.

steve, san francisco, 2012-04-22 16:57:41
Must admit I'm wary about the May 15th advisory committee on Home HIV testing. If people can obtain an HIV tester anywhere such as drugstores, how can this ability be abused or misused? With out-dated US laws against people with HIV still in-tact, will rampant HIV testers be a potential threat to those infected, (I.E., by making them more susceptible to the unjust laws still on the books)?

comments 1 - 3 (of 3 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    slimcuteguy
    Asheville
    North Carolina


    jimmy807
    San Antonio
    Texas

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.